Policy & Regulation
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
...
GSK secures US and EU fast-track designations for efimosfermin in MASH
27 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has received Breakthrough Therapy Designation from the US Food and Drug Administration, as well as ...
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
27 April 2026 - Pharmaceutical company Shield Therapeutics plc (LSE: STX) announced on Monday that its partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc, has enrolled the first patient in...
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
27 April 2026 - Veradermics Inc (NYSE:MANE), a late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, on Monday announced positive topline results fr...
Thermo Fisher scientific agrees to sell microbiology business to Astorg
27 April 2026 - Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) announced on Monday that it has signed a definitive agreement to sell its microbiology business to As...
Cantargia reports early remission data from nadunolimab trial in MDS and AML
27 April 2026 - Swedish biotechnology company Cantargia AB (STO:CANTA) on Monday reported early results from an ongoing Phase 1b/2a trial evaluating nadunolimab in combination therapies for high-risk ...